Published November 15, 2012
Intarcia Therapeutics said it raised $210 million, enabling the biotechnology company to fund late-stage clinical trials for a new diabetes treatment without forming an alliance with a major drug maker. [ read more ]
Utah Business Social
2014 Fast 50 EventAug 28, 2014Utah Business magazine along with presenting sponsors Kirton McConkie, CBIZ, MHM, LLC and Newmark...